Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 -mutant (HER2m) non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases (mets): Results from DESTINY-Lung05 (DL-05).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Chongqing University, Chongqing Cancer Hospital, Sir Run Run Shaw Hospital, Zhejiang University, Hunan Cancer Hospital, Zhengzhou University, First Affiliated Hospital of Zhengzhou University, Zhejiang Cancer Hospital, Second Affiliated Hospital of Anhui Medical University, Shandong Tumor Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Peking University Cancer Hospital, The First Affiliated Hospital, Sun Yat-sen University, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Affiliated Hospital of Hebei University, Shanghai Medical College of Fudan University, Fudan University, Zhongshan Hospital, Liaoning Cancer Hospital & Institute, AstraZeneca (United States), Jilin Province Tumor Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162685447